CYCC लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Jun 2024 @ 20:56):
Our systems believe the stock currently is undervalued by 0.01% compare to its pairs and should correct upwards.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases...

Stats
आज की मात्रा	279 948
औसत मात्रा	876 103
बाजार मूल्य	2.55M
EPS	$-2.27 ( Q1 \| 2024-05-14 )
अगली कमाई की तारीख	( $-0.830 ) 2024-08-14
Last Dividend	$0.150 ( 2016-07-13 )
Next Dividend	$0 ( N/A )
P/E	-0.0800 (Sector) 42.63 (Industry) 24.32
ATR14	$0.0210 (1.20%)

AADI -2.65%

ABCL 1.79%

ABCM 0.04%

ABEO -2.37%

ABIO -1.68%

ABOS 1.64%

ABSI 3.07%

ABUS -2.24%

ABVX -3.53%

ACAD -0.54%

ACER -17.95%

ACET -4.44%

ACGN 1.29%

ACHL -4.15%

ACHV -1.72%

ACIU -0.50%

ACLX -0.09%

ACRV -4.79%

ACST -1.63%

ACXP 0.65%

ADAG 4.64%

ADAP -2.79%

ADGI 0.87%

ADIL 0.54%

ADMA -2.54%

ADPT -0.30%

ADTX -3.47%

ADVM -4.29%

ADXN -1.60%

AEON -3.74%

AEZS -3.51%

AFMD -1.40%

AGEN -1.58%

AGIO -2.04%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW -13.88%

AKBA -3.54%

AKRO -2.77%

AKTX 4.08%

AKUS 0.00%

ALBO 0.00%

ALDX -2.25%

ALEC -3.90%

ALGS -2.41%

ALKS -0.21%

ALLK -8.90%

ALLO -6.46%

ALLR -3.17%

ALNA 3.16%

ALNY 1.80%

ALPN 0.02%

ALPX 0.00%

ALRN -1.67%

ALT -9.34%

ALVR -0.58%

ALXN 0.00%

ALXO -10.65%

ALZN 4.78%

AMRN 0.26%

AMTI -3.13%

ANAB 0.50%

ANEB -1.52%

ANGN 0.00%

ANIX -1.62%

ANL -6.60%

ANNX -0.65%

ANPC -3.15%

APGE -1.01%

APGN 8.48%

APGNW 30.65%

APLM 1.56%

APLS -0.02%

APLT -4.28%

APM -1.47%

APOP 0.38%

APRE 2.29%

APTO 4.70%

APTX 3.17%

APVO 0.18%

ARAV -13.39%

ARCT -3.81%

ARDS -14.23%

ARDX -0.66%

ARGX -0.80%

ARNA 0.00%

ARPO -0.90%

ARQT -0.50%

ARTL -2.50%

ARTLW 0.00%

ARVN 5.19%

ARWR -1.86%

ASLN -4.71%

ASMB -7.01%

ASND -0.91%

ATAI -1.46%

ATHA 5.94%

ATHE 1.12%

ATHX -33.50%

ATNF 0.99%

ATOS 2.91%

ATRA -2.89%

ATXI 1.93%

ATXS -1.22%

AUPH -0.99%

AURA -0.15%

AUTL -1.87%

AVBP -2.86%

AVEO 0.00%

AVIR -0.15%

AVRO -1.41%

AVTE -4.86%

AVTX -1.25%

AVXL -2.72%

AXLA 0.00%

AXSM -1.73%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO 0.73%

BCAB 3.59%

BCDA -2.07%

BCDAW -41.77%

BCEL 0.00%

BCLI 2.60%

BCRX 1.32%

BCTX 8.12%

BCTXW -22.52%

BCYC 0.85%

BDRX -5.14%

BDTX -0.85%

BEAM 0.24%

BFRA -2.91%

BGNE -2.19%

BIOR -3.40%

BIVI 1.18%

BLCM -6.68%

BLI -5.88%

BLPH 0.00%

BLRX -0.85%

BLTE -0.62%

BLU 0.03%

BLUE -0.66%

BMEA -9.60%

BMRN 0.36%

BNOX -2.22%

BNTC -2.11%

BNTX -1.26%

BOLD -7.90%

BOLT -0.18%

BPMC -1.27%

BPTH 1.86%

BPTS -13.47%

BRNS -0.74%

BRTX -2.36%

BTAI 22.46%

BTTX 53.33%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 3.33%

CABA 0.35%

CADL -0.97%

CALA 0.00%

CALC -1.77%

CALT -0.59%

CAPR -2.40%

CARA -0.63%

CARM 12.16%

CASI -1.67%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS -7.00%

CCCC -5.40%

CCXI 0.00%

CDAK 0.00%

CDIO -2.02%

CDIOW 24.00%

CDMO -2.96%

CDMOP 0.04%

CDT -10.57%

CDTTW -39.60%

CDTX -1.92%

CDXC -0.41%

CDXS 4.48%

CELC -3.85%

CELU -1.50%

CELUW 11.80%

CERC -1.68%

CERE -0.86%

CERO -3.60%

CEROW -10.18%

CFRX -27.95%

CGEM -2.74%

CGEN -2.79%

CGON -0.29%

CGTX -5.11%

CHMA -6.00%

CHRS -0.32%

CINC 0.00%

CING -3.70%

CINGW 34.95%

CKPT -2.88%

CLBS -16.75%

CLDX -2.27%

CLGN 0.34%

CLLS -4.15%

CLNN 2.42%

CLNNW 0.00%

CLRB 7.24%

CLSD 1.60%

CLSN -0.68%

CLVS 0.00%

CMMB -0.01%

CMND 3.63%

CMPI 0.00%

CMPX -8.03%

CMRA 0.00%

CMRAW 33.33%

CMRX -2.71%

CNCE 0.00%

CNSP -40.07%

CNST 0.00%

CNTA -0.91%

CNTB -2.25%

CNTX -6.85%

COCP -2.02%

COEPW 32.45%

COGT -2.89%

CORT 2.17%

COYA -1.46%

CPRX -0.76%

CRBP -1.89%

CRBU -4.83%

CRDF -1.77%

CRGX 1.28%

CRIS -0.38%

CRNX -5.81%

CRSP 1.03%

CRTX 2.63%

CRVO -2.50%

CRVS 1.12%

CSBR -1.59%

CTCX -1.63%

CTIC 0.06%

CTMX -3.29%

CTNM -0.65%

CTXR 0.04%

CUE 3.53%

CVAC -1.98%

CVKD 0.15%

CWBR 2.80%

CYAD -12.96%

CYCC 9.75%

CYCCP 5.49%

CYCN 0.43%

CYT -2.27%

CYTK -2.01%

CYTO -2.73%

DARE 7.54%

DAWN 0.30%

DBTX -0.81%

DBVT -2.08%

DFFN 10.28%

DICE 0.06%

DMAC 32.63%

DNLI -1.85%

DNTH -6.31%

DOMH -1.58%

DRMA -1.10%

DRMAW -1.25%

DRNA 0.00%

DRTS 1.85%

DRTSW 0.00%

DRUG 0.95%

DSGN -1.51%

DTIL 1.36%

DYAI 9.68%

EARS -1.77%

EDIT -2.52%

EDSA -1.00%

EFTR 7.18%

EFTRW -51.85%

EIGR -9.21%

ELAB -1.00%

ELDN 7.98%

ELEV -4.56%

ELOX 7.69%

ELTX -0.88%

ELVN -4.30%

ELYM 1.05%

ENGN 1.67%

ENGNW 0.12%

ENLV 2.54%

ENOB 1.79%

ENSC 5.11%

ENTA -0.49%

ENTO -0.07%

ENTX 0.69%

ENVB 1.10%

EPIX -0.10%

EPRX -2.97%

EPZM 0.00%

EQ 0.86%

EQRX -2.09%

EQRXW 0.00%

ERAS -1.20%

ERNA 0.00%

ERYP 1.30%

ESLA 4.30%

ESLAW 87.05%

ETNB -0.57%

ETON 1.49%

ETTX 0.00%

EVAX -2.14%

EVGN 3.88%

EVLO 0.00%

EWTX 0.00%

EXAI -0.95%

EXEL -0.25%

EYEG -0.69%

EYEN 1.51%

EYPT -0.12%

FATE -8.05%

FBIO 0.59%

FBIOP 0.92%

FBLG -16.60%

FBRX -0.04%

FDMT -4.56%

FENC -1.29%

FGEN -4.70%

FHTX 1.43%

FIXX 0.77%

FMTX 0.00%

FNCH 8.87%

FOLD -2.63%

FREQ 4.76%

FRLN 0.15%

FRTX 0.00%

FSTX 0.00%

FTRE -0.47%

FULC -3.34%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT -6.29%

GANX -1.42%

GBIO -2.12%

GBT 0.01%

GDTC 0.50%

GERN -4.09%

GHRS -1.60%

GLMD -2.15%

GLPG -2.26%

GLSI 2.80%

GLTO -0.57%

GLUE -1.58%

GLYC -10.03%

GMAB -0.47%

GMDA -18.25%

GMTX 0.00%

GNCA -85.71%

GNFT -0.52%

GNLX 0.89%

GNPX 0.98%

GNTA 3.94%

GOSS -7.84%

GOVX 3.17%

GOVXW -49.04%

GPCR -6.51%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS 0.00%

GRTX 0.00%

GTHX 0.68%

GUTS -5.31%

GXGXW 41.67%

GYRE -7.16%

HALO -0.89%

HARP 0.09%

HCWB -3.75%

HEPA 2.80%

HGEN -84.62%

HILS 5.66%

HLVX -1.91%

HOOK 1.13%

HOTH -2.70%

HOWL -2.14%

HRMY 0.83%

HRTX 1.80%

HSTO 0.00%

HUMA 1.22%

HUMAW -0.01%

IBRX -4.26%

ICCC 0.22%

ICPT 0.21%

ICU 17.92%

ICUCW 20.20%

ICVX -0.91%

IDRA -23.04%

IDYA -1.52%

IFRX -2.66%

IGMS -0.15%

IKNA 0.60%

IKT 1.42%

IMAB -0.87%

IMCR -2.60%

IMGN 0.02%

IMGO 0.00%

IMMP 4.55%

IMMX -6.90%

IMNM -1.56%

IMNN 0.88%

IMPL -27.27%

IMRA 15.96%

IMRN -1.18%

IMRX -0.84%

IMTX -1.58%

IMTXW 6.00%

IMUX 1.56%

IMV 0.00%

IMVT -3.77%

INAB 0.59%

INBX 0.47%

INCY -0.94%

INDP 11.07%

INFI -52.38%

INKT -0.01%

INM -2.20%

INMB 2.66%

INO -1.80%

INSM -0.88%

INTS -2.75%

INVA 0.22%

INZY 1.14%

IOBT -11.02%

IONS 0.11%

IOVA -2.31%

IPA 2.46%

IPHA 5.58%

IPSC -1.95%

IRON -2.35%

ISEE 0.38%

ITOS -1.44%

ITRM 1.67%

IVA 6.96%

IVVD -3.72%

JAGX 1.04%

JANX -4.22%

JAZZ -0.55%

JNCE 0.00%

JSPR -5.92%

JSPRW 20.88%

JUNS 0.00%

JUNSW 0.00%

KA -3.94%

KALV -1.90%

KDNY 0.22%

KMPH -0.34%

KNSA -2.71%

KNTE -0.38%

KOD -7.11%

KPRX 0.96%

KPTI -1.38%

KRBP -10.00%

KRON 1.05%

KROS -1.18%

KRRO -6.34%

KRTX 0.03%

KRYS -0.79%

KTRA 16.36%

KTTA 8.16%

KTTAW 0.92%

KURA -1.78%

KYMR -2.22%

KYTX -3.49%

KZIA 5.16%

KZR -1.49%

LABP 0.57%

LBPH -0.93%

LBPS 0.00%

LBPSW 14.81%

LEGN 1.65%

LENZ -4.01%

LEXX 0.00%

LEXXW -14.63%

LGND -1.30%

LGNDV 0.00%

LGVN -9.04%

LIAN -8.28%

LIFE 2.70%

LIPO -7.10%

LIXT -5.24%

LIXTW 63.57%

LJPC -0.32%

LMNL 0.12%

LOGC 0.87%

LPCN -3.16%

LPTX -1.10%

LQDA -0.24%

LRMR -1.92%

LSTA -4.06%

LTRN 0.50%

LUMO -1.32%

LVTX 0.00%

LXEO -4.33%

LXRX -2.06%

LYEL -34.91%

LYRA 2.83%

MACK 0.10%

MBIO -9.40%

MBRX -1.72%

MCRB 1.12%

MDGL -2.42%

MDNA -13.16%

MDWD 0.10%

MDXG -2.58%

MEIP -0.13%

MESO -1.78%

MGNX -2.91%

MGTA -7.74%

MGTX -2.68%

MGX -2.68%

MIRM -1.09%

MIRO 0.59%

MIST 1.54%

MITO 0.00%

MLEC -7.69%

MLECW 2.31%

MLND -5.36%

MLTX -0.76%

MLYS -5.62%

MNKD -1.05%

MNMD 0.21%

MNOV 2.11%

MNPR -5.01%

MOLN 0.28%

MOR 1.06%

MORF -3.67%

MREO -4.32%

MRKR 2.68%

MRNA -4.91%

MRNS -4.04%

MRSN -2.62%

MRTX -0.17%

MRUS 0.18%

MRVI -1.82%

MTCR -1.29%

MTEM 4.46%

MTP -18.50%

MURA -1.08%

MYMD 8.38%

NAMS 1.37%

NAMSW 0.43%

NAUT 1.14%

NBRV 0.71%

NBSE -1.56%

NBTX 8.61%

NCNA 1.09%

NERV -1.87%

NEXI 2.60%

NGM -1.28%

NGNE -1.98%

NKGN 5.88%

NKGNW 8.00%

NKTR -3.72%

NKTX -4.57%

NLSP -2.77%

NLSPW 26.67%

NMRA -0.46%

NMTR -42.97%

NOVN -24.84%

NRBO 10.92%

NRIX -0.58%

NRSN -6.16%

NRSNW 0.00%

NRXP -4.14%

NRXPW 18.33%

NRXS 4.82%

NTBL 5.06%

NTEC -12.45%

NTHI 0.00%

NTLA -6.20%

NTRBW -31.07%

NUVL -1.93%

NVAX -1.93%

NVCT 3.59%

NVIV -34.28%

NXTC -2.94%

NYMX -0.05%

OABI 0.40%

OABIW -10.06%

OBIO -2.99%

OBSV 0.00%

OCEA 0.00%

OCGN 3.81%

OCS -1.02%

OCUL -1.91%

OCUP 1.97%

ODT -4.27%

OKYO 1.51%

OLMA -5.20%

OMER -0.90%

OMGA 5.42%

ONCO 4.90%

ONCR -3.08%

ONCS 31.87%

ONCT -1.87%

ONCY 0.99%

ONTX -0.47%

ONVO 0.99%

OPNT 0.00%

OPT 3.09%

ORGS -4.53%

ORIC -3.56%

ORMP 15.09%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.81%

OVID -1.43%

OYST 0.00%

PALI -0.87%

PASG -1.30%

PBLA -7.50%

PBM -7.64%

PBYI 1.69%

PCSA 0.00%

PCVX -0.37%

PDSB -1.11%

PEPG 0.48%

PGEN -3.01%

PHAR 1.51%

PHAS 0.00%

PHAT -1.06%

PHIO -3.57%

PHIOW 36.47%

PHVS -7.22%

PHXM -5.20%

PIRS 0.58%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -0.73%

PLUR 6.01%

PMN 0.72%

PMVP -1.19%

PNT 0.16%

PPBT -4.26%

PRAX 0.95%

PRDS 0.93%

PRLD 0.00%

PROG -3.47%

PROK 0.45%

PRQR -0.01%

PRTA -2.31%

PRTC 0.49%

PRTG -0.50%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV -5.11%

PSTX -1.16%

PTCT -0.28%

PTE -0.82%

PTGX -1.70%

PTIXW -49.04%

PULM 2.60%

PXMD 0.00%

PYPD 0.07%

PYXS 2.61%

QLGN -3.72%

QNCX 5.70%

QNRX 0.37%

QSI -11.84%

QSIAW -3.13%

QTTB -4.54%

QURE -0.45%

RAIN -1.63%

RANI 6.42%

RAPT -2.29%

RARE 1.10%

RCKT -8.09%

REGN -0.66%

RENB -3.11%

REPL -2.82%

RETA 0.02%

REUN -0.89%

REVB -1.40%

REVBU 3.46%

REVBW 4.38%

RGLS -4.91%

RGNX -5.40%

RIGL -3.28%

RLAY -4.59%

RLMD 0.33%

RLYB -0.34%

RNA -0.42%

RNAC -5.65%

RNAZ -0.96%

RNXT 1.88%

ROIV -2.08%

ROIVW 4.56%

RPHM -0.31%

RPRX 0.32%

RPTX -2.05%

RUBY 2.70%

RVLP -32.05%

RVMD -1.07%

RVMDW -30.00%

RVNC 1.70%

RVPH -1.19%

RVPHW 1.62%

RXDX 0.09%

RXRX -3.41%

RYTM -6.25%

RYZB 0.02%

RZLT 1.29%

SABS -1.37%

SABSW -11.81%

SAGE 1.38%

SANA -4.15%

SAVA -0.26%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 5.50%

SCPH -0.51%

SCPS 0.00%

SEEL -4.09%

SEER -0.44%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -1.23%

SGMT -2.17%

SGTX -2.56%

SIOX 22.63%

SLDB -5.08%

SLGL 4.00%

SLN -4.21%

SLNO -2.92%

SLRX 5.23%

SLS -2.99%

SMMT -2.62%

SNDX 0.82%

SNGX -3.02%

SNPX -0.81%

SONN -1.08%

SPPI -0.49%

SPRB 0.30%

SPRC -4.17%

SPRO 0.04%

SRNE -34.00%

SRPT -1.85%

SRRA 0.00%

SRRK -2.48%

SRZN -2.45%

STAB 0.00%

STOK -4.80%

STRO -2.51%

STSA 0.00%

STTK -4.78%

SURF -0.93%

SVRA -3.26%

SWTX 0.72%

SYBX -1.94%

SYRS -1.72%

TALS -0.73%

TARA -8.06%

TARS 0.12%

TBPH 0.48%

TCBP 2.73%

TCDA 0.00%

TCON -2.43%

TCRR 0.00%

TCRT 1.59%

TCRX 2.58%

TECH -0.21%

TENX -1.27%

TERN -7.59%

TFFP -3.05%

TGTX -2.71%

THRX 0.12%

TIL -0.20%

TLC 0.00%

TLSA -4.13%

TNGX -2.16%

TNXP -6.35%

TNYA -8.76%

TPST 2.30%

TRDA -3.86%

TRVI 1.15%

TRVN 5.02%

TSHA -23.94%

TSVT -3.19%

TTNP -9.27%

TVTX 0.63%

TYRA -7.24%

UBX -2.12%

UNCY -3.38%

URGN -1.45%

UTHR -0.32%

VACC 11.36%

VALN -2.89%

VAXX 87.50%

VBIV 0.78%

VBLT -8.77%

VCEL -0.09%

VCNX 10.35%

VCYT -1.23%

VERA -2.81%

VERU 0.78%

VERV -3.05%

VIGL 5.11%

VINC 1.62%

VIR 0.43%

VIRI -1.57%

VIRX 2.40%

VKTX -1.34%

VLON -13.04%

VNDA -2.36%

VOR -2.02%

VRCA 0.28%

VRDN -4.23%

VRNA -1.00%

VRPX 0.38%

VRTX 0.35%

VSTM -3.74%

VTGN -0.46%

VTVT -2.97%

VTYX -0.21%

VXRT -2.26%

VYGR -1.66%

VYNE -3.47%

VYNT 7.78%

WINT -3.24%

WVE -4.60%

XBIO 0.93%

XBIT 0.21%

XCUR 3.58%

XENE -2.91%

XERS 2.38%

XFOR 3.71%

XLO 1.58%

XLRN 0.00%

XNCR 0.34%

XOMA -3.14%

XOMAO 0.36%

XOMAP -0.82%

XRTX -8.92%

YMAB -1.80%

ZGNX 0.00%

ZIOP -0.88%

ZLAB -3.48%

ZNTL -2.86%

ZSAN 0.00%

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Schwartz Brian	Buy	12 500	Common Stock
2024-01-29	Schwartz Brian	Buy	12 500	Stock Option (right to buy)
2023-12-21	Mcbarron Paul	Buy	1 886	Common Stock
2023-12-21	Mcbarron Paul	Buy	1 886	Warrants (right to buy)
2023-12-21	Rombotis Spiro George	Buy	6 070	Common Stock

INSIDER POWER
100.00
Last 94 transactions
Buy: 3 599 901 \| Sell: 12

सहसंबंध (AI algo v.1.1b): Undervalued: 0.01% $1.745 paired level. (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

मात्रा सहसंबंध

लंबा: 0.23 (neutral)

छोटा: -0.62 (weak negative)

Signal:(51.055) Neutral

Cyclacel Pharmaceuticals सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
OZEM	1
ALVO	0.839
PAL	0.828

10 सबसे अधिक नकारात्मक सहसंबंध
BKHA	-0.824

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Cyclacel Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र

-0.28
( neutral )

-0.72
( moderate negative )

0.00
( neutral )

-0.54
( weak negative )

0.00
( neutral )

-0.55
( weak negative )

Cyclacel Pharmaceuticals वित्तीय

Annual	2023
राजस्व:	$420 000
सकल लाभ:	$389 000 (92.62 %)
EPS:	$-26.51

FY	2023
राजस्व:	$420 000
सकल लाभ:	$389 000 (92.62 %)
EPS:	$-26.51

FY	2022
राजस्व:	$0
सकल लाभ:	$-32 000.00 (0.00 %)
EPS:	$-32.23

FY	2021
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-5.20

Financial Reports:

No articles found.

Cyclacel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Cyclacel Pharmaceuticals Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.150	2016-07-13
Last Dividend	$0.150	2016-07-13
Next Dividend	$0	N/A
Payout Date	2016-08-01
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.150	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-26)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2016	$0.150	0.01%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
13 Jul 2016	$0.150	09 Jun 2016	17 Jul 2016	01 Aug 2016

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-44.01	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-3.21	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-6.38	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	-0.00764	-1.000	-0.0764	0.0764	[0 - 1]
currentRatioTTM	0.579	0.800	-2.10	-1.684	[1 - 3]
quickRatioTTM	0.496	0.800	-1.789	-1.431	[0.8 - 2.5]
cashRatioTTM	0.335	1.500	9.25	10.00	[0.2 - 2]
debtRatioTTM	0.00341	-1.500	9.94	-10.00	[0 - 0.6]
interestCoverageTTM	-239.02	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-7.50	2.00	-2.50	-5.00	[0 - 30]
freeCashFlowPerShareTTM	-7.50	2.00	-3.75	-7.50	[0 - 20]
debtEquityRatioTTM	-0.00952	-1.500	-0.0381	0.0571	[0 - 2.5]
grossProfitMarginTTM	0.132	1.000	-1.129	-1.129	[0.2 - 0.8]
operatingProfitMarginTTM	-57.49	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-463.52	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0728	0.800	-2.85	-2.28	[0.5 - 2]
Total Score				-6.17

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.104	1.000	-0.112	0	[1 - 100]
returnOnEquityTTM	-6.38	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.50	2.00	-2.50	-7.50	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.50	2.00	-2.50	-5.00	[0 - 30]
payoutRatioTTM	-0.00764	1.500	-0.0764	0.0764	[0 - 1]
pegRatioTTM	-0.00208	1.500	-3.35	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-21.68	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.52

Cyclacel Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.